Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as dexpantenol [Bepantol]
dexpantenol · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| 3 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Corticosteroids | DRUG | As prescribed |
| Placebo | DRUG | As prescribed |
| capecitabine [Xeloda] | DRUG | As prescribed |
| dexpantenol [Bepantol] | DRUG | As prescribed |
Inclusion Criteria: * adult patients, \>=18 years of age; * breast cancer or colorectal cancer patients; * treated with oral Xeloda for \<=5 days; * lack of hand-foot syndrome (palmar-plantar erythrodysesthesia). Exclusion Criteria: * existence of clinical symptoms suggesting hand-foot syndrome; ...
Top 20 of 87 competitors
Dexpantenol was studied as a prophylactic treatment for hand-foot syndrome in breast cancer patients receiving oral Xeloda (capecitabine). Hand-foot syndrome is a common side effect of capecitabine therapy. The Phase 3 trial evaluated whether dexpantenol could prevent this skin reaction in patients undergoing treatment for breast cancer.
Dexpantenol is developed by Roche Holding AG, which trades under the ticker RHHBY. Roche conducted the Phase 3 clinical trial of dexpantenol for hand-foot syndrome prophylaxis in breast cancer patients treated with capecitabine.
Dexpantenol is in Phase 3 clinical development. One Phase 3 trial has been completed, and no active trials are currently ongoing. The completed trial enrolled 598 patients and evaluated dexpantenol for the prevention of hand-foot syndrome in breast cancer patients receiving oral Xeloda (capecitabine).
Dexpantenol has been studied in one completed Phase 3 clinical trial, NCT00661102, titled "A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine)." The trial enrolled 598 patients with breast cancer in Brazil and was placebo-controlled.
Yes, dexpantenol is also known as dexpantenol [Bepantol]. Bepantol is a brand name under which dexpantenol is marketed. In the context of the Phase 3 trial, dexpantenol was investigated for preventing hand-foot syndrome in breast cancer patients treated with capecitabine.